A Phase 3 interventional study of AGN-199201 and Vehicle to AGN-199201 in Erythema and Rosacea, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-18.
Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Erythema with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Erythema · United States.
Among the 55 studies in Erythema with a site in United States, this one is the 2nd largest by enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2014, is one of 5 in phase 3, and was the 16th registered.
131 studies on the registry are indexed under Erythema; 17 are open to participants now.
Browse Erythema studies →8 of the 55 studies in Erythema with a site in United States are open now. Recruiting first, the newest first:
Medicines Development for Global Health · Sites in United States, Benin, Côte D'Ivoire and 3 more countries
Ages 18+
Good Molecules, LLC · Sites in United States
Ages 18–75 · Healthy volunteers
University of Nevada, Las Vegas · Sites in United States
Ages 18+
Acorn Biolabs Inc. · Sites in United States, Canada
Ages 18+ · Healthy volunteers
Henry Ford Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Erythema studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 440 is above the median of 50 across 114 interventional studies indexed under Erythema.
Median enrollment 52 across the 52 interventional studies, 104 across the 3 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 55 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
AbbVie has 7 studies filed under Erythema — fewer than ten, so there is no comparison to draw.
4 of the studies in Erythema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07172659Medicines Development for Global HealthEfficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction | 2027-01 |
| NCT06477172Acorn Biolabs Inc.Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures | 2027-02 |
| NCT07789639Good Molecules, LLCA Clinical Study to Evaluate the Efficacy and SPF of Two Test Materials According to an Adaptation of the Guidelines of the FDA Sunscreen Drug Products for Over-the-Counter Human Use | 2027-02-24 |
| NCT02876107M.D. Anderson Cancer CenterCarboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Erythema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Moderate to severe persistent facial erythema associated with rosacea.
Exclusion Criteria:
AGN-199201 applied to the face once daily for 29 days.
Drug: AGN-199201
Vehicle to AGN-199201 applied to the face once daily for 29 days.
Drug: Vehicle to AGN-199201
AGN-199201 applied to the face once daily for 29 days.
Vehicle to AGN-199201 applied to the face once daily for 29 days.
Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales
The investigator assessed the patient's overall severity of erythema in the treatment area on the 5 point CEA scale (ranging from 0=clear skin with no signs of erythema to 4=severe erythema/fiery redness). The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) on both CEA and SSA from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.
Time frame: Baseline, Day 29 (Hours 3, 6, 9, and 12)
Percentage of Patients With at Least a 2-Grade Decrease From Baseline on the SSA 5-point Scale
The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.
Time frame: Baseline, Day 29 (Hours 3, 6, 9, and 12)
Percent Change From Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA)
Rosacea facial redness in the treatment area was measured by DIA. The percent change was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. Baseline was defined as the measurement at predose on Day 1. A negative number change from baseline indicates a decrease in facial redness (improvement), and a positive number change from baseline indicates an increase in facial redness (worsening).
Time frame: Baseline, Day 29 (Hours 3, 6, 9, and 12)
Percentage of Patients Reporting Treatment Satisfaction on the Satisfaction Assessment for Rosacea Facial Redness (SA-RFR) Questionnaire Item 9
The SA-RFR questionnaire item 9 is completed by patients assessing treatment satisfaction on facial redness. Patients reporting treatment satisfaction as "very satisfied" or "satisfied" are noted. The percentage of patients was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29.
Time frame: Day 29 (Hours 3, 6, 9, and 12)
Change From Baseline on the SA-RFR Questionnaire Item #4
The SA-RFR questionnaire item 4 is completed by patients assessing how much their face burned due to facial redness on a 5 point scale (range 0=does not burn at all and 4=burns a lot). Patients were evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. A lower score change from baseline (negative number) indicates a decrease in facial redness (improvement), and a higher score change from baseline (positive number) indicates an increase in facial burning (worsening).
Time frame: Baseline, Day 29 (Hours 3, 6, 9, and 12)
Percentage of Patients With at Least a 1-Grade Decrease From Baseline on the SSA 5-point Scale
The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 1 grade decrease (improvement) on the SSA from baseline at Day 1 hour 1. Baseline was defined as the measurement at predose on Day 1.
Time frame: Baseline, Day 1 (Hour 1)
| Milestone | AGN-199201 | Vehicle |
|---|---|---|
| Started | 222 | 218 |
| Completed | 210 | 213 |
| Not completed | 12 | 5 |
| Withdrew: Personal reasons | 4 | 4 |
| Withdrew: Lost to follow-up | 4 | 0 |
| Withdrew: Adverse event | 4 | 1 |
The investigator assessed the patient's overall severity of erythema in the treatment area on the 5 point CEA scale (ranging from 0=clear skin with no signs of erythema to 4=severe erythema/fiery redness). The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) on both CEA and SSA from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.
| Percentage of Patients | AGN-199201 | Vehicle |
|---|---|---|
| Day 29, Hour 3 (N=222, 216) | 11.9 | 5.5 |
| Day 29, Hour 6 (N=222, 216) | 15.5 | 8.3 |
| Day 29, Hour 9 (N=222, 216) | 17.7 | 6.0 |
| Day 29, Hour 12 (N=222, 216) | 14.8 | 6.0 |
The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 2 grade decrease (improvement) from baseline was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on day 29. Baseline was defined as the measurement at predose on Day 1.
| Percentage of Patients | AGN-199201 | Vehicle |
|---|---|---|
| Day 29, Hour 3 | 20.1 | 11.1 |
| Day 29, Hour 6 | 23.3 | 12.9 |
| Day 29, Hour 9 | 23.3 | 12.0 |
| Day 29, Hour 12 | 25.0 | 11.5 |
Rosacea facial redness in the treatment area was measured by DIA. The percent change was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. Baseline was defined as the measurement at predose on Day 1. A negative number change from baseline indicates a decrease in facial redness (improvement), and a positive number change from baseline indicates an increase in facial redness (worsening).
| Percent Change | AGN-199201 | Vehicle |
|---|---|---|
| Day 29, Hour 3 | -21.37 ± 94.693 | 61.54 ± 428.943 |
| Day 29, Hour 6 | -14.22 ± 97.835 | 75.09 ± 498.844 |
| Day 29, Hour 9 | -8.00 ± 92.893 | 71.18 ± 398.072 |
| Day 29, Hour 12 | -5.35 ± 98.547 | 74.16 ± 415.301 |
The SA-RFR questionnaire item 9 is completed by patients assessing treatment satisfaction on facial redness. Patients reporting treatment satisfaction as "very satisfied" or "satisfied" are noted. The percentage of patients was evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29.
| Percentage of Patients | AGN-199201 | Vehicle |
|---|---|---|
| Day 29, Hour 3 | 45.9 | 27.5 |
| Day 29, Hour 6 | 43.7 | 24.3 |
| Day 29, Hour 9 | 43.2 | 23.4 |
| Day 29, Hour 12 | 41.9 | 24.8 |
The SA-RFR questionnaire item 4 is completed by patients assessing how much their face burned due to facial redness on a 5 point scale (range 0=does not burn at all and 4=burns a lot). Patients were evaluated over the 12-hour evaluation period (hours 3, 6, 9, and 12) postdose on Day 29. A lower score change from baseline (negative number) indicates a decrease in facial redness (improvement), and a higher score change from baseline (positive number) indicates an increase in facial burning (worsening).
| Scores on a Scale | AGN-199201 | Vehicle |
|---|---|---|
| Baseline | 1.8 ± 0.83 | 1.9 ± 0.85 |
| Day 29, Hour 3 | -1.5 ± 0.93 | -1.5 ± 0.95 |
| Day 29, Hour 6 | -1.5 ± 0.91 | -1.5 ± 0.98 |
| Day 29, Hour 9 | -1.5 ± 0.97 | -1.5 ± 0.96 |
| Day 29, Hour 12 | -1.5 ± 0.97 | -1.5 ± 0.95 |
The patient assessed the overall severity of rosacea facial redness in the treatment area on the 5 point SSA scale (ranging from 0=no signs of unwanted redness to 4=severe redness). The percentage of patients with at least a 1 grade decrease (improvement) on the SSA from baseline at Day 1 hour 1. Baseline was defined as the measurement at predose on Day 1.
| Percentage of Pateints | AGN-199201 | Vehicle |
|---|---|---|
| Percentage of Patients With at Least a 1-Grade Decrease From Baseline on the SSA 5-point Scale | 30.2 | 17.4 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AGN-199201 | — | 1/222 (0.5%) | 0/222 (0%) |
| Vehicle | — | 3/218 (1.4%) | 0/218 (0%) |
| Event | AGN-199201 | Vehicle |
|---|---|---|
| Atrial FibrillationCardiac disorders | 0/222 | 1/218 |
| Cardiac FailureCardiac disorders | 0/222 | 1/218 |
| ArteriosclerosisCardiac disorders | 0/222 | 1/218 |
| PneumoniaRespiratory, thoracic and mediastinal disorders | 0/222 | 1/218 |
| FallGeneral disorders | 1/222 | 0/218 |
| Age, Customized(Participants) | AGN-199201 | Vehicle | Total |
|---|---|---|---|
| 18 to 64 years | 189 | 194 | 383 |
| >=65 years | 33 | 24 | 57 |
| Sex: Female, Male(Participants) | AGN-199201 | Vehicle | Total |
|---|---|---|---|
| Female | 172 | 175 | 347 |
| Male | 50 | 43 | 93 |
The record gives a start of May 2014, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxymetazoline